• The European Medicines Agency committee recently recommended revoking the EU marketing authorisation for TAVNEOS®, affecting Fresenius Medical Care's treatment portfolio for kidney patients across the region.
• This regulatory setback raises questions about how Fresenius Medical Care will adapt its European therapy offering while continuing to invest in digital kidney care initiatives.
• We’ll now examine how the potential loss of TAVNEOS® in the EU reshapes Fresenius Medical Care’s longer-term investment narrative.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Fresenius Medical Care Investment Narrative Recap

To invest in Fresenius Medical Care, you need to believe in its ability to grow kidney care services and improve profitability while managing regulatory and reimbursement pressures. The EMA committee’s move against TAVNEOS® looks more like a portfolio setback than a thesis breaker, but it does add incremental regulatory risk on top of existing concerns around U.S. margins and treatment volume trends.

In this context, the June 2026 launch of the kinexus digital platform for home dialysis stands out. It underlines Fresenius Medical Care’s push into connected, at home kidney care, which many investors see as an important medium term catalyst for better patient retention and more resilient revenue, even as specific drugs in the treatment portfolio, such as TAVNEOS®, come under regulatory pressure.

Yet, against this promising digital story, investors should be aware that...

Read the full narrative on Fresenius Medical Care (it's free!)

Fresenius Medical Care's narrative projects €21.1 billion revenue and €1.3 billion earnings by 2029. This requires 3.0% yearly revenue growth and about a €0.4 billion earnings increase from €944.7 million today.

Uncover how Fresenius Medical Care's forecasts yield a €43.69 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting earnings to climb toward about €1.6 billion by 2029 and saw faster margin expansion, but after the TAVNEOS® setback and the risk that Value Based Care growth may not translate cleanly into profits, you should assume those forecasts might be revised and consider how differently others view the same stock.

Explore 4 other fair value estimates on Fresenius Medical Care - why the stock might be worth just €43.69!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Fresenius Medical Care research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Fresenius Medical Care research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Fresenius Medical Care's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.